Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05083260
Recruitment Status : Recruiting
First Posted : October 19, 2021
Last Update Posted : May 2, 2022
Sponsor:
Information provided by (Responsible Party):
BioVie Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A 28-day phase 2a, double-blind, placebo-controlled (1:1), multi-center study of 20 mg NE3107, twice daily of safety, potential drug-drug interactions, and MDS-UPDRS defined activity in patients with Parkinson's disease . Study will enroll 40 patients that are currently taking immediate release levodopa/ carbidopa (IRLC) and have a practically defined early morning off-state for IRLC. Day one- baseline UPDRS and IRLC PK sampling; day 2- start NE3107 dosing, assess UPDRS during onset and NE3107 PK sampling, rescue meds as needed after 4 hours; day 3 and 14- NE3107 + IRLC UPDRS assessment and PK sampling; day 28- NE3107 + IRLC UPDRS assessments. Optional overnight stays in clinic prior to Day 1-3, 14, and 28.

Condition or disease Intervention/treatment Phase
Parkinson Disease Drug: NE3107 Drug: placebo Phase 1 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's Disease (PD) Participants Treated With Carbidopa/Levodopa and NE3107
Actual Study Start Date : January 4, 2021
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : August 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: NE3107
orally administered NE3107 20 mg twice daily (BID)
 Drug: NE3107
NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease
Placebo Comparator: placebo
orally administered placebo, twice daily
 Drug: placebo
Hard gelatin capsule containing only common excipients for oral formulations


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change from baseline (day 1) in Motor disease society- Unified Parkinson's disease rating scale Part III total score for the patient in the "off-state" (without L-dopa for previous eight hours) [ Time Frame: measured on day 1, 2, 3, 14, and 28 ]
    Unified Parkinson's disease rating scale Part III total score is the cumulative score of a 33 question assessment of disease impact on patient's ability to move, with each part scored on a scale of 0-4, with 0 being no effect of disease and 4 being severe disease. a total score of 0 indicates no disease and a total score of 132 indicates the most severe disease

  2. Change from baseline in the length of time during which L-dopa therapy is ineffective in reducing motor symptoms of disease (OFF time) [ Time Frame: off time will be measured/recorded every day from day 2 to day 27 ]
    The total sum of time in which a patient self categorizes themselves as in the "off" state determined by diary entries. 0 hours is the minimum/best score, which indicates continuous L-dopa-like activity for the 24 hour period. 24 hours is the worst score and indicates that there was no L-dopa-like benefit at any time during the 24 hour period.

  3. Change from baseline in average Motor disease society- Unified Parkinson's disease rating scale Part III total score measured over the course of 8 hours after taking L-dopa and/or NE3107 [ Time Frame: measured on day 1, 2, 3, 14, and 28 ]
    An average score will be calculated from assessments of the Unified Parkinson's disease rating scale Part III total score, which is the cumulative score of a 33 question assessment of disease impact on patient's ability to move, with each question scored on a scale of 0-4, with 0 being no effect of disease and 4 being severe disease. a total score of 0 indicates no disease and a total score of 132 indicates the most severe disease. Scores will be collected several times during the eight hours following L-dopa and/or NE3107 administration.

  4. Motor disease society- Unified Parkinson's disease rating scale Part I total score [ Time Frame: measured on day 1, 2, 3, 14, and 28 ]
    the cumulative score of a 13 question assessment of disease impact on patient's cognitive impairment, with each question scored on a scale of 0-4, with 0 being no effect of disease and 4 being severe disease. a total score of 0 indicates no disease and a total score of 42 indicates the most severe disease. This test asks about the impact of disease on cognition, but does not directly measure cognitive capability.

  5. Motor disease society- Unified Parkinson's disease rating scale Part 2 total score [ Time Frame: measured on day 1, 2, 3, 14, and 28 ]
    the cumulative score of a 13 question assessment of disease impact on patient's Motor Aspects of Experiences of Daily Living, with each question scored on a scale of 0-4, with 0 being no effect of disease and 4 being a severe effect. a total score of 0 indicates no disease and a total score of 42 indicates the most severe disease.

  6. Change from baseline in the length of time during which L-dopa-like effects are felt by the patient [ Time Frame: baseline and day 1, 2, 3, 14, and 28 ]
    The total sum of time in which a patient self categorizes themselves as in the "on" state, with or without dyskinesia determined by diary entries. 0 hours is the minimum/worst score, which indicates no L-dopa-like activity for the 24 hour period. 24 hours is the best score and indicates that there was no L-dopa-like benefit at any time during the 24 hour period.

  7. change from baseline in L-dopa induced dyskinesia measured with the abnormal involuntary movement scale (AIMS) [ Time Frame: AIMS will be measured during the 8 hour period of observation on Day 1, 2, 3, 14, and 28 ]
    AIMS is a 12-item clinician-rated scale to assess severity of dyskinesias (orofacial movements and extremity and truncal movements) in patients taking L-dopa. Questions assess the overall severity, incapacitation, and the patient's level of awareness of the movements, and distress associated with them. Questions are scored from 0 (no symptom) to 4 (severe). the minimum total score of 0 indicates no dyskinesia and the maximum total score of 48 indicates severe dyskinesia.

  8. change from baseline in time to onset of L-dopa-like activity [ Time Frame: measured on Day 1, 2, 3, 14, and 28 ]
    Length of time from L-dopa administration to beginning of L-dopa activity producing "on-state". Patient self assessment of the time L-dopa-like activity begins after L-dopa administration. A decrease in the time to onset may shorten the time in the off-state and be considered a patient benefit. An increase in time to onset may lengthen time in the off-state and be considered a general worsening of response to treatment.

  9. Change from baseline in Non-Motor Symptom Assessment Scale for Parkinson Disease (NMSS) [ Time Frame: Measured on Day 1, 2, 3, 14, and 28 ]
    The Non-Motor Symptoms Scale (NMSS) is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. The scale can be used for patients at all stages of PD. For each question, scores of severity (0 to 3, with 0 being none and 3 being major source of distress) and frequency (1 to 4, 1= rarely and 4 = very frequent) are recorded and the product of the two calculated. The sum of the products yields the overall score. The minimum total score of 0 indicates no non-motor symptoms and the maximum score of 360 indicates severe disease.

  10. change in area under the levodopa plasma concentration vs. time curve when administered alone compared to being co-administered with NE3107 [ Time Frame: Blood samples will be collected on Day 1, 2, 3, and 14 ]
    the plasma concentration vs time curve for L-dopa will be calculated from the L-dopa concentration in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours after L-dopa administration on days on which NE3107 is not administered (Day 1) and three days on which NE3107 is co-administered (Day 2, 3, and 14). Changes in L-dopa area under the curve could be associated with changes in activity against motor symptoms of disease.

  11. Change in the maximum plasma concentration (Cmax) of levodopa when administered alone compared to being co-administered with NE3107. [ Time Frame: Blood samples will be collected on Day 1, 2, 3, and 14 ]
    the maximum plasma concentration for L-dopa will be determined in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours after L-dopa administration on days on which NE3107 is not administered (Day 1) and three days on which NE3107 is co-administered (Day 2, 3, and 14). Changes in L-dopa Cmax could be associated with changes in activity against motor symptoms of disease.

  12. The area under the NE3107 plasma concentration vs. time curve when administered alone compared to being co-administered with [ Time Frame: Blood samples will be collected on Day 2, 3, and 14 ]
    the plasma concentration vs time curve for NE3107 will be calculated from the NE3107 concentration in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours

  13. Change in the maximum plasma concentration (Cmax) of NE3107 when administered alone compared to being co-administered with L-dopa [ Time Frame: Blood samples will be collected on Day 2, 3, and 14 ]
    the maximum plasma concentration for NE3107 will be determined in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours after NE3107 administration


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men or women at least 30 and no more 80 years of age
  2. Diagnosis of PD consistent with UK Brain Bank Criteria or MDS Research Criteria for the Diagnosis of PD, with bradykinesia and a clear motor response to levodopa
  3. Stable doses of all PD medications for at least 4 weeks prior to Screening
  4. Carbidopa/levodopa dose of at least 300 mg daily, distributed over a minimum of 3 dosing intervals during waking hours
  5. Participants must have history of motor fluctuations with reliable early-morning OFF episodes and a history of a good response to levodopa, in the judgement of the investigator

  6. If of reproductive potential, willing and able to use a highly effective form of birth control during the study and for 30 days following last dose of study drug. Examples of highly effective forms of birth control are:

    1. Surgical sterility (via vasectomy, hysterectomy, or bilateral tubal ligation) or postmenopausal status in females
    2. Sexual partner who is sterile or of the same sex
    3. Double-barrier method (any combination of physical and chemical methods)
    4. Intrauterine device in females not containing hormones.
  7. Able and willing to comply with study drug administration, scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study
  8. Investigational Review Board/Ethics Committee-approved consent form signed and date by the participant
  9. Assessed as an appropriate and suitable candidate by the Enrollment Authorization Committee (EAC)

Exclusion Criteria:

  1. Diagnosis of secondary or atypical parkinsonism
  2. Severe or disabling fluctuations or dyskinesias that would, in the opinion of the investigator, interfere with completion of the study
  3. Clinically significant cognitive impairment
  4. Clinically significant hallucinations or delusions
  5. Clinically significant orthostatic hypotension
  6. Currently active major depression as determined by BDI-II score of >19
  7. Previous surgical procedure for PD (Duopa, DBS, etc.)
  8. History of small bowel or gastric surgery
  9. History of clinically significant GI abnormality (inflammatory bowel disease, significant motility disorder or emesis of any cause, etc.)
  10. Use of long-acting levodopa formulations (Sinemet CR, ER, Rytary, etc.)
  11. Routine use of proton pump inhibitors or H2 blockers
  12. Routine use of medications that may influence gastric motility (opiates, TCA antidepressants, anticholinergics, etc.)
  13. Other clinically significant medical, surgical, psychiatric, or laboratory abnormality that, in the judgment of the investigator, is likely to interfere with study compliance or assessment of safety or efficacy
  14. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 2.5 times the upper limit of normal (ULN)
  15. Significant renal impairment as determined by creatinine clearance (CrCL) less than or equal to 50 mL/min

  16. Participant has an ECG or clinical evidence of potentially unstable heart disease, including the following:

    1. QTcF > 470 msec females; > 450 msec males
    2. Complete right or left bundle branch block
    3. Ischemia or myocardial infarct within 1 year prior to the Screening Visit
    4. Clinically significant atrial or ventricular dysrhythmia; the heart must be in predominantly normal sinus rhythm
    5. Second- or third-degree AV block
    6. Heart failure of NYHA classification III or greater
    7. Serious cardiomyopathy or cardiac structural abnormality
    8. Symptomatic coronary artery or ischemic cardiac disease
    9. Any other cardiac condition that the Investigator feels may predispose the participant to ischemia or arrhythmia.
  17. Current (or within past 12 months) diagnosis or history of substance abuse, including alcohol (excluding nicotine or caffeine) by Diagnostic and Statistical Manual of Mental Disorders 5 criteria, or positive urine drug screen for tetrahydrocannabinol or any drugs that may affect participant safety or interfere with efficacy assessments
  18. Medical or recreational use of marijuana or CBD within 3 months of the Screening Visit
  19. Active suicidal ideation within 1 year prior to Screening Visit as determined by a positive response to Question 4 or 5 on the C-SSRS
  20. Currently lactating or pregnant, or planning to become pregnant during the study
  21. Current participation in another investigational clinical study and/or receipt of any investigational drug within 90 days prior to screening
  22. Prior randomization into this study
  23. Diabetes requiring insulin treatment
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05083260


Contacts
Layout table for location contacts
Contact: Clarence Ahlem ‪(858) 255-4568 cahlem@bioviepharma.com
Contact: Joseph Djan 858-733-2433 jdjan@bioviepharma.com

Locations
Layout table for location information
United States, Colorado
Rocky Mountain Movement Disorders Center Recruiting
Englewood, Colorado, United States, 80113
Contact: study    303-357-5459    kortiz@kumarneuro.com   
United States, Florida
Parkinson's Disease & Movement Disorders Center Of Boca Raton Recruiting
Boca Raton, Florida, United States, 33486
Contact: study coordinator    561-392-1818 ext 3    mcarvalho@ParkinsonsCenter.org   
Velocity Recruiting
Hallandale Beach, Florida, United States, 33009
Contact: Study coordinator    954-455-5757      
Charter Research Recruiting
Winter Park, Florida, United States, 32792
Contact: lead study coordinator    407-337-1000    Jessica.Garaycoa@charterresearch.com   
United States, Michigan
Quest Research Institute Recruiting
Farmington Hills, Michigan, United States, 48334
Contact: study coordinator    248-957-8940      
United States, North Carolina
Duke University Recruiting
Durham, North Carolina, United States, 27705
Contact: Study administrator    919-668-1538    lisa.gauger@duke.edu   
M3 Wake Recruiting
Raleigh, North Carolina, United States, 27612
Contact: Study Coordinator    919-781-2514    ccook@wakeresearch.com   
Wake Research Recruiting
Raleigh, North Carolina, United States, 27612
Contact: study coordinator    919-420-6067    ccook@wakeresearch.com   
United States, Ohio
University of Toledo Recruiting
Toledo, Ohio, United States, 43614
Contact: Study Coordinator    419-383-6728    Julia.Spears@utoledo.edu   
Sponsors and Collaborators
BioVie Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: BioVie Inc.
ClinicalTrials.gov Identifier: NCT05083260    
Other Study ID Numbers: NM201
First Posted: October 19, 2021    Key Record Dates
Last Update Posted: May 2, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BioVie Inc.:
MDS-UPDRS
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
 Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases